Compared with CML cells bearing the BCR-ABL fusion gene, imatinib monotherapy had limited antitumor effects on MM cells with ABL amplification as shown by cell proliferation assays. Here, BCR is linked to chronic myelogenous leukemia, BCR-ABL1 positive.